Skip to main content
. 2021 Oct 4;11(10):164. doi: 10.1038/s41408-021-00558-5

Fig. 3. Overall (OS), relapse-free survival (RFS), cumulative incidences of relapse (CIR), and non-relapse mortality (NRM) of the transplant cohort.

Fig. 3

With a median FU of 7.6 months (range: 0.1–24.1 months) estimated 2-year OS, RFS, CIR, and NRM probabilities of the entire cohort were 73%, 71%, 23%, and 12%, respectively. OS was estimated as time between allo-HSCT and death or date of last follow-up in surviving patients, while RFS was calculated as time from allo-HSCT until relapse or death without relapse censoring those patients, who had not relapsed until and were alive at date of last follow-up. CIR and NRM were considered as competing risks and calculated using cumulative incidence (CI) estimates employing Gray test for univariate comparisons.